BiomX reports FY2023 net loss $26.2M; completes APT acquisition and $50M financing

BiomX Inc.

FY2023 net loss $26.2M vs $28.3M prior year; R&D expenses $16.7M.
Completed acquisition of Adaptive Phage Therapeutics (March 2024), gaining BX211 for DFO.
Closed $50M private placement led by Deerfield and AMR Action Fund; used to fund BX004 and BX211 through key data readouts.
Cash, restricted cash and short-term deposits $15.9M at Dec 31, 2023; company states sufficient for 12 months post-financing.
BX211 Phase 2 DFO trial enrolled 32 of 45 patients; topline results expected Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 3, 2024, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2023.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-029582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.